{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:15:09Z","timestamp":1771640109974,"version":"3.50.1"},"reference-count":9,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2020,6,30]]},"DOI":"10.5582\/ddt.2020.03043","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T22:09:11Z","timestamp":1593209351000},"page":"117-121","source":"Crossref","is-referenced-by-count":13,"title":["Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma"],"prefix":"10.5582","volume":"14","author":[{"given":"Hiroyuki","family":"Ohashi","sequence":"first","affiliation":[{"name":"Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sora","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomitsu","family":"Miyagaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Kadono","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kiyohara Y, Uhara H, Ito Y, Matsumoto N, Tsuchida T, Yamazaki N. Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance. J Dermatol. 2018; 45:408-415.","DOI":"10.1111\/1346-8138.14227"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Wu Y, Ju Q, Jia K, Yu J, Shi H, Wu H, Jiang M. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). Int J Cancer. 2018; 143:45-51.","DOI":"10.1002\/ijc.31301"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nishijima TF, Muss HB, Shachar SS, Moschos SJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. Cancer Treat Rev. 2016; 45:30-37.","DOI":"10.1016\/j.ctrv.2016.02.006"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nakamura Y, Kitano S, Takahashi A, Tsutsumida A, Namikawa K, Tanese K, Abe T, Funakoshi T, Yamamoto N, Amagai M, Yamazaki N. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget. 2016; 7:77404-77415.","DOI":"10.18632\/oncotarget.12677"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Weide B, Martens A, Hassel JC, <i>et al.<\/i> Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016; 22:5487-5496.","DOI":"10.1158\/1078-0432.CCR-16-0127"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fujisawa Y, Yoshino K, Otsuka A, <i>et al.<\/i> Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population. Br J Dermatol. 2018; 179:213-215.","DOI":"10.1111\/bjd.16427"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bartlett EK, Flynn JR, Panageas KS, Ferraro RA, Sta Cruz JM, Postow MA, Coit DG, Ariyan CE. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. Cancer. 2020; 126:76-85.","DOI":"10.1002\/cncr.32506"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant. 2013; 48:452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nakamura Y, Tanaka R, Maruyama H, Ishitsuka Y, Okiyama N, Watanabe R, Fujimoto M, Fujisawa Y. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies. Jpn J Clin Oncol. 2019; 49:431-437.","DOI":"10.1093\/jjco\/hyy201"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/14\/3\/14_2020.03043\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T03:45:32Z","timestamp":1595043932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/14\/3\/14_2020.03043\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2020.03043","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]}}}